Published by
Ministry of Health, Labour and Welfare

Translated by
Pharmaceuticals and Medical Devices Agency



# Revision of Precautions

## Sitagliptin phosphate hydrate/ipragliflozin L-proline

January 21, 2020

### Therapeutic category

Antidiabetic agents

### Non-proprietary name

Sitagliptin phosphate hydrate/ipragliflozin L-proline

### Safety measure

Precautions should be revised in the package insert.

**Pharmaceuticals and Medical Devices Agency**

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

Revision in line with the Instructions for Package Inserts of Prescription Drugs, etc. PSEHB Notification No. 0608-1 by the Director of Pharmaceutical Safety and Environmental Health Bureau, MHLW, dated June 8, 2017 (New instructions): Revised language is underlined.

| Current | Revision |
|---|---|
| 11. ADVERSE REACTIONS<br>11.1. Clinically Significant Adverse Reactions<br>Anaphylactic reaction | 11. ADVERSE REACTIONS<br>11.1. Clinically Significant Adverse Reactions<br>Shock, anaphylaxis |

**Pharmaceuticals and Medical Devices Agency**

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp